Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics
World Journal of Gastrointestinal Surgery · 27.06.2026 · 18 (6)
DOI: 10.4240/wjgs.118659 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Surgery, online erschienen am 27.06.2026. Verfasst von Jin-Ping Li und 3 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Obesity and type 2 diabetes mellitus (T2DM) represent a major global health challenge. Although sleeve gastrectomy (SG) effectively induces weight loss and improves glycemic control, long-term outcomes can be limited by weight regain and metabolic fluctuations. Semaglutide, a glucagon-like peptide-1 receptor agonist, complements surgical effects through glucose-lowering and weight-loss mechanisms. We hypothesize that combining SG with semaglutide postoperatively will yield superior and more sustained improvements in glycemic control, weight reduction, and metabolic parameters compared to surgery alone, addressing a critical gap in the long-term management of obese T2DM patients. AIM To assess how SG and semaglutide affects metabolic markers and blood glucose control rate in individuals with T2DM and obesity. METHODS This retrospective cohort study analyzed 80 obese patients with T2DM admitted between December 2022 and June 2025. Patients included observation group (n = 40, SG plus semaglutide) and control group (n = 40, SG alone). We compared postoperative glycemic control rates and changes in fasting plasma glucose, 2-hour postprandial glucose, glycated hemoglobin, serum total cholesterol, triglycerides, low-density lipoprotein cholesterol, body mass index, homeostasis model assessment of β-cell function, and homeostasis model assessment of insulin resistance. RESULTS The observation group had a greater percentage of blood glucose control following therapy than the control group. When compared to pre-treatment levels, both groups’ fasting plasma glucose, 2-hour postprandial glucose, glycated hemoglobin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and body mass index significantly decreased, with the observation group experiencing a larger reduction (P < 0.05). Simultaneously, the observation group demonstrated superior improvement in homeostasis model assessment of β-cell function and a greater reduction in homeostasis model assessment of insulin resistance compared to the control group (P < 0.05). The incidence of adverse outcomes after surgery did not differ significantly according to statistical analysis between the two groups (P > 0.05). CONCLUSION SG paired with semaglutide significantly improves the rate of blood glucose control in obese patients with T2DM, demonstrating superior metabolic benefits and islet function enhancement compared to surgery alone.
Zitieren
APA
Li, J., Wang, L., Dong, L., & Bai, C. (2026). Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics. World Journal of Gastrointestinal Surgery, 18(6). https://doi.org/10.4240/wjgs.118659
Vancouver
Li J, Wang L, Dong L, Bai C. Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics. World Journal of Gastrointestinal Surgery. 2026;18(6). doi:10.4240/wjgs.118659
BibTeX
@article{Li2026,
author = {Li, Jin-Ping and Wang, Lei and Dong, Li and Bai, Chun},
title = {Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics},
journal = {World Journal of Gastrointestinal Surgery},
year = {2026},
volume = {18},
number = {6},
doi = {10.4240/wjgs.118659}
}
EUVIMED